The Evolution of Diagnosis from Symptom Onset to Death in Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) Compared to Parkinson's Disease (PD)

Overview

Journal J Neurol

Specialty Neurology

Date 2023 Mar 27

PMID 36971841

Authors

Diane M A Swallow

Carl E Counsell

Affiliations

Soon will be listed here.

Abstract

Background: Misdiagnosis and delayed diagnosis in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are common. Few studies have systematically evaluated the diagnostic process from symptom onset to death in representative cohorts.

Methods: All PSP/CBD cases (n = 28/2) and age-sex matched Parkinson's disease (PD) cases (n = 30) were identified from a UK prospective incident Parkinsonism cohort. Medical and research records were reviewed to compare median times from first index symptom to key diagnostic milestones and the nature/timing of secondary care referral and review.

Results: Index symptoms were similar apart from more tremor in PD (p < 0.001) and more impaired balance (p = 0.008) and falls (p = 0.004) in PSP/CBD. PD was diagnosed a median 0.96 years after index symptom. In PSP/CBD the median times from index symptom to identifying parkinsonism and then including PSP/CBD in the differential diagnosis and the final diagnosis were 1.88, 3.41 and 4.03 years, respectively (all p < 0.001). Survival from symptom onset in PSP/CBD and PD was not significantly different (5.98 vs 6.85 years, p = 0.72). More diagnoses (p < 0.001) were considered in PSP/CBD. Prior to diagnosis, PSP/CBD patients had more recurrent emergency attendances (33.3% vs 10.0%, p = 0.01) and were referred to more specialities than PD (median 5 vs 2). Time to any outpatient referral (0.70 vs 0.03 years, p = 0.025) and to specialist movement disorder review (1.96 vs 0.57 years, p = 0.002) was longer in PSP/CBD.

Conclusions: The duration and complexity of the diagnostic journey were greater in PSP/CBD than age-sex matched PD but can be improved. In this older cohort, there was little difference in survival from symptom onset in PSP/CBD and age-sex matched PD.

Citing Articles

The potential of exosomal biomarkers: Revolutionizing Parkinson's disease: How do they influence pathogenesis, diagnosis, and therapeutic strategies?.

Akbari-Gharalari N, Ghahremani-Nasab M, Naderi R, Chodari L, Nezhadshahmohammad F AIMS Neurosci. 2024; 11(3):374-397.

PMID: 39431275 PMC: 11486621. DOI: 10.3934/Neuroscience.2024023.

Accuracy of routinely collected hospital administrative discharge data and death certificate ICD-10 diagnostic coding in progressive supranuclear palsy and corticobasal syndrome: a systematic review and validation study.

Swallow D, Counsell C J Neurol. 2024; 271(6):2929-2937.

PMID: 38609666 PMC: 11136796. DOI: 10.1007/s00415-024-12280-w.

Total Patient Delay: A Comparison of Patient and Clinician/Health System Delays in the Diagnosis of Progressive Supranuclear Palsy and Corticobasal Syndrome.

Swallow D, Murchie P, Counsell C Mov Disord Clin Pract. 2024; 11(5):478-487.

PMID: 38369623 PMC: 11078481. DOI: 10.1002/mdc3.13990.

The role of exosomes in the diagnosis of Parkinson's disease.

Shi Q, Kang W, Liu Z, Zhu X Heliyon. 2023; 9(10):e20595.

PMID: 37928387 PMC: 10622621. DOI: 10.1016/j.heliyon.2023.e20595.

References

Birdi S, Rajput A, Fenton M, Donat J, Rozdilsky B, Robinson C . Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002; 17(6):1255-64. DOI: 10.1002/mds.10211. View

Mamarabadi M, Razjouyan H, Golbe L . Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?. Mov Disord Clin Pract. 2019; 5(6):603-606. PMC: 6277372. DOI: 10.1002/mdc3.12678. View

Litvan I, Agid Y, Goetz C, Jankovic J, Wenning G, Brandel J . Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997; 48(1):119-25. DOI: 10.1212/wnl.48.1.119. View

Chio A . ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol. 2000; 246 Suppl 3:III1-5. DOI: 10.1007/BF03161081. View

Hughes A, Daniel S, Ben-Shlomo Y, Lees A . The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002; 125(Pt 4):861-70. DOI: 10.1093/brain/awf080. View

Househam E, Swash M . Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement?. J Neurol Sci. 2000; 180(1-2):76-81. DOI: 10.1016/s0022-510x(00)00418-4. View

Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G . Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology. 2016; 86(6):566-76. DOI: 10.1212/WNL.0000000000002350. View

Koepsell T, Gill D, Chen B . Stability of clinical etiologic diagnosis in dementia and mild cognitive impairment: results from a multicenter longitudinal database. Am J Alzheimers Dis Other Demen. 2013; 28(8):750-8. PMC: 3876285. DOI: 10.1177/1533317513504611. View

Ling H, OSullivan S, Holton J, Revesz T, Massey L, Williams D . Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010; 133(Pt 7):2045-57. DOI: 10.1093/brain/awq123. View

10.

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

11.

Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M . Delayed diagnosis in ALS: the problem continues. J Neurol Sci. 2014; 343(1-2):173-5. DOI: 10.1016/j.jns.2014.06.003. View

12.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

13.

Kraemer M, Buerger M, Berlit P . Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2009; 112(2):103-5. DOI: 10.1016/j.clineuro.2009.10.014. View

14.

Okubadejo N, Ojo O, Oshinaike O . Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria. BMC Neurol. 2010; 10:1. PMC: 2806862. DOI: 10.1186/1471-2377-10-1. View

15.

Sleeman I, Chung Che Z, Counsell C . Risk of fracture amongst patients with Parkinson's disease and other forms of parkinsonism. Parkinsonism Relat Disord. 2016; 29:60-5. DOI: 10.1016/j.parkreldis.2016.05.026. View

16.

Donaghy C, Dick A, Hardiman O, Patterson V . Timeliness of diagnosis in motor neurone disease: a population-based study. Ulster Med J. 2008; 77(1):18-21. PMC: 2397016. View

17.

Painous C, Marti M, Simonet C, Garrido A, Valldeoriola F, Munoz E . Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study. Parkinsonism Relat Disord. 2020; 74:67-73. DOI: 10.1016/j.parkreldis.2020.03.003. View

18.

Femi O, Ibrahim A, Aliyu S . Clinical profile of parkinsonian disorders in the tropics: Experience at Kano, northwestern Nigeria. J Neurosci Rural Pract. 2012; 3(3):237-41. PMC: 3505306. DOI: 10.4103/0976-3147.102589. View

19.

Breen D, Evans J, Farrell K, Brayne C, Barker R . Determinants of delayed diagnosis in Parkinson's disease. J Neurol. 2013; 260(8):1978-81. DOI: 10.1007/s00415-013-6905-3. View

20.

Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P . Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci. 2006; 250(1-2):45-9. DOI: 10.1016/j.jns.2006.06.027. View